2/10
08:05 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/10
05:36 am
avxl
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [Seeking Alpha]
Medium
Report
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory [Seeking Alpha]
2/9
02:45 pm
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
2/9
10:16 am
avxl
Anavex Life Sciences Q1 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Anavex Life Sciences Q1 Earnings Call Highlights [Yahoo! Finance]
2/9
07:41 am
avxl
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
2/9
07:30 am
avxl
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Low
Report
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
2/3
08:18 am
avxl
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 [Yahoo! Finance]
Low
Report
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 [Yahoo! Finance]
2/3
07:30 am
avxl
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Low
Report
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
1/15
04:33 am
avxl
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
Low
Report
Anavex Life Sciences Highlights Oral Alzheimer's Drug Blarcamesine, Precision Strategy at JPM Conference [Yahoo! Finance]
1/13
07:30 am
avxl
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
Medium
Report
Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease
1/8
08:13 pm
avxl
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
Low
Report
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm
1/8
10:00 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
1/8
07:30 am
avxl
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Medium
Report
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
1/6
12:40 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
1/6
09:55 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
1/6
07:30 am
avxl
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Low
Report
Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
1/1
10:00 am
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Low
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
12/30
04:15 pm
avxl
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Medium
Report
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
12/24
10:30 am
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Low
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/22
08:02 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
12/18
07:30 am
avxl
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
Low
Report
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
12/17
10:20 am
avxl
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
Low
Report
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
12/15
08:06 am
avxl
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
Medium
Report
Anavex Life Sciences (NASDAQ:AVXL) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $24.00 price target on the stock.
12/12
05:32 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
Medium
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease [Yahoo! Finance]
12/12
04:05 pm
avxl
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Low
Report
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease